Focused On-demand Library for Terminal nucleotidyltransferase 5A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

HBV X-transactivated gene 11 protein; HBV XAg-transactivated protein 11

Alternative UPACC:

Q96IP4; A8K7U4; Q5TF86; Q8NFZ9; Q9BW32; Q9NXV5


Terminal nucleotidyltransferase 5A, also known as HBV X-transactivated gene 11 protein, plays a crucial role in bone health. It functions as a cytoplasmic non-canonical poly(A) RNA polymerase, catalyzing the transfer of adenosine molecules to mRNA poly(A) tails. This process is vital for the polyadenylation of mRNA encoding extracellular matrix constituents and other genes essential for bone mineralization.

Therapeutic significance:

The protein's involvement in Osteogenesis imperfecta 18, a severe connective tissue disorder characterized by bone fragility, underscores its therapeutic potential. Understanding the role of Terminal nucleotidyltransferase 5A could open doors to potential therapeutic strategies for treating bone-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.